 NEW YORK, Oct. 14, 2021 PRNewswire -- Elevation Oncology, Inc. Nasdaq: ELEV, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced an investigator-presented case series from the Cancer Molecular Screening and Therapeutics MoST study at the Australasian Gastro-Intestinal Trials Group AGITG 2021 Annual Scientific Meeting, taking place virtually October 12-15, 2021. The presentation was selected as one of four Best of the Best at the meeting and provides a select case series of patients treated on the MoST program, which uses genomic profiling to characterize molecular changes in tumors from patients with treatment-refractory advanced cancers and matches those patients with targeted oncology agents. 